Celsius Therapeutics is a community of scientists, technologists, clinicians and drug hunters leveraging single-cell RNA sequencing and genomic analysis to develop life-changing medicines.
Celsius Therapeutics is translating single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer.
Celsius Therapeutics was founded in 2018 by Jeffrey Bluestone, Vijay Kuchroo, Christoph Lengauer, Aviv Regev, and Ramnik Xavier. The company is headquartered in Cambridge, Massachusetts.
Celsius Therapeutics is charting a new course of target and drug discovery by understanding the specific cells, among many others, that are key players in disease and by identifying the genes that are triggering their malfunction.
Celsius Therapeutics is applying a systematic approach to single-cell sequencing, combining massive datasets and complex algorithms in order to discover first-in-class precision therapies that have a transformative impact on the lives of patients with autoimmune diseases and cancer.
Celsius Therapeutics is backed by Third Rock Ventures, GV, Casdin Capital, Alexandria Venture Investments, Heritage Provider Network, Amgen Ventures, Amplitude Ventures, Catalio Capital, and others. The company raised $83M in additional financing, comprised of a Series A extension and a Series B round, on Mar 24, 2022. This brings Celsius Therapeutics' total funding to $148M to date.